# Adjuvant Chemotherapy for High Risk Stage I Lung Adenocarcinoma

> **NCT03380468** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Fudan University** · enrollment: 300 (estimated)

## Conditions studied

- Lung Neoplasms

## Interventions

- **DRUG:** cisplatin plus pemetrexed

## Key facts

- **NCT ID:** NCT03380468
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-01-01
- **Primary completion:** 2024-01-01
- **Final completion:** 2025-12-31
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2023-07-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03380468

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03380468, "Adjuvant Chemotherapy for High Risk Stage I Lung Adenocarcinoma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03380468. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*